84 results
8-K
EX-99.1
XLO
Xilio Therapeutics Inc
14 May 24
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
7:45am
; the potential for Xilio to leverage its research platform to develop tumor-activated bispecific and cell engager molecules; the potential benefits of any … limitation, general market conditions; Xilio’s ability to successfully achieve the benefits of the strategic portfolio reprioritization and workforce
8-K
EX-99.1
ny4 szvfn6ghz6v
1 Apr 24
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
4:15pm
8-K
649ltovaq5wr
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
EX-99.2
c25bcf8l6dsuax
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
EX-99.1
1fftfyr447gfbfmt
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
EX-10.2
r63y0q0
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
ahq224fh92ec5y9ths
7 Dec 23
Other Events
7:45am
8-K
EX-99.1
zfzf tfmpq
7 Dec 23
Other Events
7:45am
8-K
EX-99.1
bylf2gda5bbbf
9 Nov 23
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
4:13pm
8-K
6b3 w19fu
3 Nov 23
Other Events
4:05pm
8-K
EX-99.1
16n 4k6yoj97pf
3 Nov 23
Other Events
4:05pm